2023
Radiotherapy Utilization and Outcomes on a Contemporary Trial for Pediatric High-Risk Hodgkin Lymphoma Study
Hoppe B, Castellino S, Pei Q, Charpentier A, Keller F, Vega R, Roberts K, Parikh R, Punnett A, Parsons S, McCarten K, Flampouri S, Kessel S, Wu Y, Cho S, Kelly K, Hodgson D. Radiotherapy Utilization and Outcomes on a Contemporary Trial for Pediatric High-Risk Hodgkin Lymphoma Study. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: s62-s63. DOI: 10.1016/j.ijrobp.2023.06.362.Peer-Reviewed Original ResearchProgression-free survivalBrentuximab vedotinABVE-PCIrradiated patientsMediastinal adenopathyRadiotherapy utilizationContemporary trialsRT modalityOpen-label phase 3 studyExcellent progression-free survivalUse of PTProgression-free survival ratesProton therapyHodgkin's lymphoma studyUtilization of RTSevere acute toxicityPhase 3 studyPediatric Hodgkin lymphomaSimilar acute toxicityAcute toxicityMATERIAL/METHODSDifferent RT modalitiesEligible patientsMedian followPediatric patientsImportance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy
Hoppe B, McCarten K, Pei Q, Kessel S, Alazraki A, Mhlanga J, Lai H, Eutsler E, Hodgson D, Roberts K, Charpentier A, Keller F, Voss S, Wu Y, Cho S, Kelly K, Castellino S. Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2023, 116: 1025-1030. PMID: 36868525, PMCID: PMC10363760, DOI: 10.1016/j.ijrobp.2023.02.020.Peer-Reviewed Original ResearchConceptsCentral reviewDeauville scoreCentral imaging reviewRadiation therapyResponse assessmentHodgkin's lymphomaImaging reviewInstitutional reviewFluorodeoxyglucose positron emission tomography/High-risk Hodgkin lymphomaPositron emission tomography responseConcordance rateEmission tomography/Real-time central reviewCohen κ statisticAreas of diseaseSystemic therapyTreating institutionPediatric patientsLymphoma trialsTomography responseTomography/Treatment allocationClinical trialsPatients
2019
Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group
Kelly KM, Cole PD, Pei Q, Bush R, Roberts KB, Hodgson DC, McCarten KM, Cho SY, Schwartz C. Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group. British Journal Of Haematology 2019, 187: 39-48. PMID: 31180135, PMCID: PMC6857800, DOI: 10.1111/bjh.16014.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCyclophosphamideDoxorubicinDrug Administration ScheduleDrug MonitoringEtoposideFemaleHodgkin DiseaseHumansIfosfamideMaleNeoplasm StagingPositron-Emission TomographyPrednisoneProspective StudiesRadiotherapy, AdjuvantRecurrenceTreatment OutcomeVincristineVinorelbineYoung AdultConceptsHigh-risk Hodgkin lymphomaABVE-PCOncology GroupHodgkin's lymphomaEarly respondersRapid early respondersEnd of chemotherapyEvent-free survivalOverall survival rateResponse-adapted therapyChildren's Oncology GroupTreatment of childrenPET-positive lesionsAlkylator exposureOS ratesActive diseaseTreat analysisPediatric patientsRadiotherapy volumeClinical evidenceEarly progressionRadiation volumeRecent trialsPositive lesionsSER patients
2015
Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children's Oncology Group
Kelly K, Cole P, Chen L, Roberts K, Hodgson D, McCarten K, Cho S, Schwartz C. Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed Very High Risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): A Report from the Children's Oncology Group. Blood 2015, 126: 3927. DOI: 10.1182/blood.v126.23.3927.3927.Peer-Reviewed Original ResearchHigh-risk Hodgkin lymphomaRapid early responseCompletion of chemotherapyABVE-PCStage IIIBOncology GroupOverall survivalPediatric patientsHodgkin's lymphomaHigh riskLong-term overall survivalDose-intensive chemotherapyRisk-adapted radiotherapyEnd of chemotherapyEvent-free survivalBone marrow involvementPhase III studyRelapse/progressionBest predictive factorChildren's Oncology GroupHigh-risk groupEnhanced risk stratificationTreatment of childrenPET-positive lesionsBulky involvement
2014
Delayed Cerebral Vasculopathy Following Cranial Radiation Therapy for Pediatric Tumors
Wang C, Roberts KB, Bindra RS, Chiang VL, Yu JB. Delayed Cerebral Vasculopathy Following Cranial Radiation Therapy for Pediatric Tumors. Pediatric Neurology 2014, 50: 549-556. PMID: 24739378, DOI: 10.1016/j.pediatrneurol.2013.09.018.Peer-Reviewed Original ResearchConceptsMedian interval periodIntracerebral hemorrhageMoyamoya syndromeInterval periodCranial radiation therapyRadiation doseIntracerebral hemorrhage casesMoyamoya casesCerebral vasculopathyCerebrovascular injuryMedian agePatient agePediatric patientsDoses of radiationDisease presentationPediatric tumorsRadiation therapyHemorrhage casesHemorrhagePatientsCerebrovasculopathySignificant associationMoyamoyaSyndromeTime of radiation